The role of Fcγ receptor polymorphisms in the response to anti-tumor necrosis factor therapy in psoriasis: A pharmacogenetic study

JAMA Dermatology

Volumn 149, Issue 9, 2013, Pages 1033-1039

  Julià, Marc ^a   Guilabert, Antonio ^a   Lozano, Francisco ^a,b   Suarez Casasús, Belén ^a,c   Moreno, Nemesio ^d   Carrascosa, Jose Manuel ^c   Ferrándiz, Carlos ^c   Pedrosa, Edurne ^e,f   Alsina Gibert, Mercè ^a   Mascaró Jr , José Manuel ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d INSTITUT CATALÀ DE LA SALUT   (Spain)

^e FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIIA; INFLIXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BIVARIATE ANALYSIS; BODY SURFACE; DISEASE SEVERITY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOGENESIS; PHARMACOGENETICS; PILOT STUDY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; REDUCTION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSORIASIS; RECEPTORS, IGG; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884684582     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.4632     Document Type: Article

References (31)

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509.
2. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009;373(9664):659-672.
3. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369(9573):1641-1657. (Pubitemid 46722637)
4. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008;359(6):613-626.
5. Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716-3725.
6. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34-47.
7. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood. 2002;99(3):754-758. (Pubitemid 34525533)
8. van Sorge NM, van der Pol WL, van de Winkel JG. FcγR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens. 2003;61(3):189-202.
9. Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fcγ receptor II is critical for human IgG2 binding. J Immunol. 1991;147(4):1338-1343.
10. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48L/R/H phenotype. Blood. 1997;90(3):1109-1114. (Pubitemid 27314146)
11. Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007;25(24):3712-3718. (Pubitemid 47372612)
12. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positivemetastatic breast cancer. J Clin Oncol. 2008;26(11):1789-1796.
13. Cañete JD, Suarez B, Hernandez MV, et al. Influence of variants of Fcγ receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumor necrosis α therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68(10):1547-1552.
14. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D. Fcγ receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor α-blocking agents. Arthritis Rheum. 2005;52(9):2693-2696. (Pubitemid 41369097)
15. Louis E, El Ghoul Z, Vermeire S, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther. 2004;19(5):511-519. (Pubitemid 38387177)
16. Arora T, Padaki R, Liu L, et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009;45(2):124-131.
17. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor α-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008;58(5):1248-1257. (Pubitemid 351705913)
18. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, I: overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850. (Pubitemid 351509656)
19. Di Renzo L, Bertoli A, Bigioni M, et al. Body composition and -174G/C interleukin-6 promoter gene polymorphism: association with progression of insulin resistance in normal weight obese syndrome. Curr Pharm Des. 2008;14(26):2699-2706.
20. Vasilopoulos Y, Manolika M, Zafiriou E, et al. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol Diagn Ther. 2012;16(1):29-34.
21. O'Rielly DD, Rahman P. Pharmacogenetics of psoriasis. Pharmacogenomics. 2011;12(1):87-101.
22. Puig L, Bordas X, Carrascosa JM, et al Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology [in Spanish]. Actas Dermosifiliogr. 2009;100(4):277-286.
23. Leppers-van de Straat FG, van der Pol WL, Jansen MD, et al. A novel PCR-based method for direct Fcγ receptor IIIa (CD16) allotyping. J Immunol Methods. 2000;242(1-2):127-132.
24. Domingo P, Muñiz-Diaz E, Baraldès MA, et al. Associations between Fcγ receptor IIA polymorphisms and the risk and prognosis of meningococcal disease. Am J Med. 2002;112(1):19-25. (Pubitemid 34113850)
25. González-Escribano MF, Aguilar F, Sánchez-Román J, Núñez-Roldán A. FcγRIIA, FcγRIIIA and FcγRIIIB polymorphisms in Spanish patients with systemic lupus erythematosus. Eur J Immunogenet. 2002;29(4):301-306. (Pubitemid 34779668)
26. Solé-Violán J, García-Laorden MI, Marcos-Ramos JA, et al. The Fcγ receptor IIA-H/H131 genotype is associated with bacteremia in pneumococcal community-acquired pneumonia. Crit Care Med. 2011;39(6):1388-1393.
27. Nieto A, Cáliz R, Pascual M, Matarán L, García S, Martín J. Involvement of Fcγ receptor IIIA genotypes in susceptibility to rheumatoid arthritis. Arthritis Rheum. 2000;43(4):735-739.
28. Villarreal J, Crosdale D, Ollier W, et al. Mannose binding lectin and FcγRIIa (CD32) polymorphism in Spanish systemic lupus erythematosus patients. Rheumatology (Oxford). 2001;40(9):1009-1012.
29. Fantuzzi F, Del Giglio M, Gisondi P, Girolomoni G. Targeting tumor necrosis factor α in psoriasis and psoriatic arthritis. Expert Opin Ther Targets. 2008;12(9):1085-1096.
30. Nishio S, Yamamoto T, Kaneko K, et al. Pharmacokinetic study and Fcγ receptor gene analysis in two patients with rheumatoid arthritis controlled by low-dose infliximab. Mod Rheumatol. 2009;19(3):329-333.
31. Morales-Lara MJ, Conesa-Zamora P, García-Simón MS, et al. Association between the FCGR3A V158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients. Scand J Rheumatol. 2010;39(6):518-520.